HYPERFINE Q3 '26 Earnings Call - HYPERFINE INC

Financial Performance:

• Third quarter 2026 revenue reached a record $6.0 million, representing a 53% sequential increase and a 73% year-over-year growth; units sold increased 75% to 14.
• Gross profit hit a record $3.4 million with gross margin expanding to 56.7%, the fifth consecutive quarter above 50%.
• Net loss narrowed to $6.0 million ($0.06 per share) from $11.0 million ($0.14 per share) in the prior year period; this included a $1.5 million non-cash gain on warrant liabilities.
• Operating loss narrowed to $7.3 million (19% improvement YoY), driven by record gross profit while operating expenses remained relatively flat (R&D down 3%, SG&A flat).
• Net cash burn decreased 29% sequentially to $5.6 million and 6% year-over-year; quarterly revenue exceeded net cash burn for the first time.
• Cash and cash equivalents stood at $37.9 million as of September 30, 2026, with a runway extending into 2028 without additional financing.
• Revenue growth was organic, with no one-time items, supported by higher average selling prices and service revenue up 31% YoY.

Guidance and Future Outlook:

• Reaffirmed full-year 2026 revenue guidance of $20–$22 million (midpoint ~55% growth YoY) based on $13.8 million year-to-date revenue.
• Raised full-year gross margin guidance range from 50–55% to 52.5–55%, reflecting confidence in durable margin gains.
• Reaffirmed full-year net cash burn guidance of $26–$28 million (approx. 10% YoY decline).
• Foreseeable 2027 growth drivers include the first full annual capital planning cycle post-Model 2 launch, continued office/concierge adoption, and international expansion.
• Contrast MRI 510K application expected to be submitted by end of 2026, with FDA clearance anticipated in Q2 or mid-year 2027 to unlock further utilization.
• Long-term vision includes expanding into the brain wellness and longevity market, with potential revenue from this vertical expected to materialize in 2028 and beyond.

Business Segments and Product Lines:

• Hospital: Largest commercial vertical; adoption expanding from ICUs to EDs, outpatient clinics, ORs, and mobile deployments; significant traction in Health Systems/IDNs via a "land and expand" model.
• Office: Continued adoption in neurology and memory clinics; early entry into concierge practices; published Neuro-PMR study showed 92% pathology concordance with conventional MRI.
• International: Launched Model 2 in Europe, UK, and Middle East (Kuwait/UAE exclusive distribution); Optifai software received CE/UKCA marking.
• Product: Model 2 driving mix and revenue growth; Optifai software release improves workflow and noise correction; contrast indication expected to significantly enhance utility in hospitals (ORs) and offices (CPT 70553 reimbursement).
• Wellness: Exploring consumer-facing AI reporting and cloud software to enable non-radiology brain imaging for longevity and wellness; no new hardware development required for this vertical.

Market and Competitive Landscape:

• Market tailwinds include the shift toward economic value in health tech, the rise of AI-driven imaging, and the expansion of care into wellness/prevention.
• Competitive advantage cited via proprietary miniaturized MRI technology with strong clinical validation (peer-reviewed studies) and superior patient preference (4:1).
• Hospital penetration strategy targets the ~70% of U.S. hospitals within systems/IDNs; follow-on orders accelerate after initial placement as champions emerge.
• International distribution model allows global expansion without proportional increases in operating expenses.
• No significant competitive threats mentioned; focus remains on scaling the platform to support the AI imaging ecosystem.

Risks and Challenges:

• Sales Cycle Length: Initial placements in national Health Systems/IDNs can take 2–3 quarters due to complex procurement, cybersecurity, and AI vetting processes.
• Regulatory: Submission of the 510K application is on track, but FDA review timelines and potential questions could impact the expected clearance date.
• Capital Budgeting: Some deals delayed as customers align purchases with next-year capital budgets, though ROI remains compelling.
• Forward-Looking Risks: Management cited standard risks regarding technology development, regulatory approvals, and market adoption uncertainties in the disclaimer.

Management Commentary and Tone:

• Tone is highly confident and optimistic; management describes Q3 as the "strongest in Hyperfine's history" and the start of a "new trajectory."
• CEO Maria Sainz emphasized the company's transformation from a niche tech firm to a broad medical and wellness platform.
• CFO Brett Hale highlighted strong operating leverage, noting that operating expenses increased less than 2% while revenue grew 53% sequentially.
• Management expressed high confidence in the sustainability of gross margins above 50% and the ability to fund operations into 2028.
• Executives conveyed a clear strategic pivot toward the "brain wellness" vertical while maintaining core medical dominance.

Analyst Questions and Answers:

• Health System Sales Cycle: Clarified that follow-on orders occur quarterly after initial regional placements (CRISTUS), while national systems take 2–3 quarters to close due to governance structures.
• Contrast Impact: Anticipated to drive unit adoption in ORs and reactivate office customers due to ROI enhancement and CPT 70553 reimbursement; expected to be a primary catalyst in H1 2027.
• Q4 Guidance: Management declined to raise Q4 guidance, noting Q4 2025 included a one-time multi-unit upgrade; 2026 growth is viewed as steady and organic rather than seasonal spikes.
• 2027 Investment: Plans for modest commercial investment to optimize sales structure but no doubling or tripling of headcount; focus on operating leverage remains.
• Gross Margin Sustainability: Confirmed margins are not one-off; driven by price increases (Model 2 launch, 2026 adjustments), improved mix, and scale, with expectations to remain in the mid-50s to high-50s.
• Unit Drivers: Q3 growth was broad-based across hospital, office, and international segments with no single dominant market.

Other Key Points:

• "No" in sales is rare; objections are typically "not now" due to budget timing or process, not economic viability.
• The company has no debt obligations and maintains $25 million of remaining capacity on its debt facility for flexibility.
• The "Sub-S" (portable MRI) is positioned as a complementary tool to conventional MRI, democratizing access rather than replacing it.
• Clinical data from the Neuro-PMR study (92% concordance, 98% with history) serves as a key validation tool for expanding use cases.
• CEO noted the broader healthcare context of patient boarding and ED crowding as a driver for demand for portable brain imaging.